Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vero cell-derived inactivated JE vaccine in healthy infants
NCT02367664Phase 3
Key facts
- Status
- Completed
- Start
- Oct 2014
- Primary completion
- Jun 2016
- Countries
- 1
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Modality
- Vaccines & Immunotherapeutics
- Conditions
- Japanese encephalitis (JE)
01
Overview
Phase 3, randomised, open-label trial of Vero cell-derived inactivated Japanese Encephalitis vaccine in Japanese encephalitis (JE), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Started Oct 2014; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Healthy Chinese infants aged 6-11 months who have never received a Japanese Encephalitis vaccine and are in good general health.
04
Registry description
Japanese encephalitis (JE) is an acute viral zoonotic disease. Neurologic manifestations of the disease range from subtle changes in behavior to serious problems, including blindness, ataxia, weakness, and movement disorders. The Japanese encephalitis virus (JEV) occurs primarily in Southeast Asian. It is spread by culicine mosquitoes, most often Culex tritaeniorhynchus. Its incubation period is 5 to 15 days.In China, JE epidemic peak season is from June to August and it mainly occurred in children. JE has ranked in top ten infectious diseases according to either incidence or mortality. JE…
Beyond the preview
Go deeper on NCT02367664.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367664.